A Randomized, Double-masked, Placebo-controlled Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Daily and Multiple Daily Ascending Doses of SHP639 Topical Ophthalmic Solution in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma (POAG)

Trial Profile

A Randomized, Double-masked, Placebo-controlled Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Daily and Multiple Daily Ascending Doses of SHP639 Topical Ophthalmic Solution in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma (POAG)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs SHP 639 (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; First in man
  • Sponsors Shire
  • Most Recent Events

    • 15 May 2017 Status changed from not yet recruiting to recruiting.
    • 03 May 2017 New trial record
    • 31 Mar 2017 According to a Shire media release, company has submitted IND application to initiate this trial in March 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top